Study wrapper · #167
Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
Editor's note
This large systematic review and meta-analysis (47 RCTs, 59,352 participants) compares cardiovascular signals for semaglutide and tirzepatide. Researchers reported that semaglutide was associated with reduced major adverse cardiovascular events (RR 0.71), cardiovascular death, myocardial infarction, and heart failure, but not stroke. For tirzepatide, only a lower myocardial-infarction risk reached significance (RR 0.63), while the MACE reduction did not (RR 0.79, CI crossing 1). The crucial caveat, which the authors stress, is that most data came from separate drug-versus-control trials rather than head-to-head comparisons — so this cannot be read as evidence that one agent is cardiovascularly superior. The asymmetry more likely reflects tirzepatide's younger, thinner cardiovascular-outcomes evidence base (its dedicated CVOT is ongoing) than a true difference. Weigh semaglutide's signal as reasonably consistent and tirzepatide's as still limited and uncertain — an evidence-maturity gap, not a verdict.
Plain-language abstract
This review combined 47 randomised trials involving more than 59,000 people to look at how semaglutide and tirzepatide relate to heart outcomes in adults with type 2 diabetes, overweight, or obesity. For semaglutide, the analysis found it was associated with fewer major heart events overall, including fewer cardiovascular deaths, heart attacks, and heart-failure events, though not fewer strokes. For tirzepatide, only the reduction in heart attacks was statistically clear; its effect on overall major heart events did not reach statistical significance, and results for cardiovascular death, heart failure, and stroke were also uncertain. The authors emphasise an important limitation: nearly all the data came from trials comparing each drug against a placebo or control, not from studies directly comparing the two drugs against each other. So the results should not be read as proof that one is better for the heart. Tirzepatide simply has less mature heart-outcome data so far, with a dedicated cardiovascular trial still underway.